

AVEO PHARMACEUTICALS INC  
Form 8-K  
June 21, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 18, 2018**

**AVEO Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-34655**  
**(Commission**

**File Number)**

**04-3581650**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: AVEO PHARMACEUTICALS INC - Form 8-K

**One Broadway, 14th Floor**

**Cambridge, Massachusetts**  
**(Address of Principal Executive Offices)**

**02142**  
**(Zip Code)**

**Registrant's telephone number, including area code: (617) 588-1960**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 18, 2018, AVEO Pharmaceuticals, Inc. (the Company) held its 2018 Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting, the Company's stockholders voted on the following proposals:

1. The following nominees were elected to the Company's Board of Directors for terms expiring at the 2019 annual meeting of stockholders.

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Mr. Michael P. Bailey	49,464,917	305,265	49,543,430
Mr. Kenneth M. Bate	47,837,807	1,932,375	49,543,430
Dr. Anthony B. Evnin	49,459,199	310,983	49,543,430
Mr. John H. Johnson	48,179,436	1,590,746	49,543,430
Dr. Robert C. Young	49,366,496	403,686	49,543,430

2. A non-binding, advisory proposal on the compensation of the Company's named executive officers was approved.

For:	48,704,579
Against:	783,037
Abstain:	282,566
Broker Non-Votes:	49,543,430

3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018 was ratified.

For:	98,604,832
Against:	498,600
Abstain:	210,180
Broker Non-Votes:	0

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AVEO Pharmaceuticals, Inc.**

By: /s/ Matthew Dallas  
Matthew Dallas  
Chief Financial Officer

Date: June 21, 2018